In order to provide complete functionality, this web site needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site including but not limited to: log in, buy products, see personalized content, switch between site cultures. It is recommended that you allow all cookies.
Learn more about our policy
EN
FR
Search for:
Navigation
Services
Preclinical solutions
Clinical trials
Biomarkers solution
ELISA Kits
Home
About us
The company
The executive team
Facilities
References
Certifications
Jobs
News & Events
News & Publications
Events
Testimonials
FAQ
Contact
News & Events
>
News & Publications
>
Partnership between Artialis & Regulaxis!
Regulaxis (France) chooses Artialis Group for the development of its new treatment against osteoarthritis!
Published on 25/06/2018
Partnership between Artialis & Regulaxis!
Paris, France and Liege, Belgium [June 25], 2018:
Artialis, specialist in the study of the musculoskeletal disorders and
Regulaxis
, an innovative French company in the treatment of osteoarthritis, announce today the signing of a 1.6 million euros contract for the preclinical and clinical development of a new molecule, Reg-O3, allowing the repair of cartilage.
Documents
Artialis-Regulaxis-Press-Release.pdf
Our latest news
01/10/2019
Review about Coll2-1 and Coll2-1NO2
20/08/2019
Coll2-1, a biomarker of cartilage degradation, is involved in osteoarthritis physiopathology
Read more
News & Publications
Events
Testimonials
© Artialis - All rights reserved
Terms & conditions
-
Privacy Policy
Made by